Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo

Haematologica. 2018 Apr;103(4):e147-e150. doi: 10.3324/haematol.2017.174060. Epub 2018 Feb 1.

Authors

Mark Kerstjens¹, Sandra S Pinhancos², Patricia Garrido Castro², Pauline Schneider², Priscilla Wander², Rob Pieters², Ronald W Stam³

Affiliations

¹ Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
² Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
³ Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands [email protected].

No abstract available

Publication types

Letter

MeSH terms

Animals
Cell Line, Tumor
Gene Rearrangement
Heterografts
Histone-Lysine N-Methyltransferase / genetics*
Humans
MAP Kinase Signaling System
Mice
Myeloid-Lymphoid Leukemia Protein / genetics*
Phosphorylation / drug effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnostic imaging
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Pyridones / pharmacology*
Pyrimidinones / pharmacology*
Tumor Burden / drug effects
ras Proteins / genetics*

Substances

KMT2A protein, human
Pyridones
Pyrimidinones
Myeloid-Lymphoid Leukemia Protein
trametinib
Histone-Lysine N-Methyltransferase
ras Proteins